• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患有镰状细胞贫血且出现急性临床事件的儿童的临床概况:一项单中心研究。

Clinical Profiles of Children With Sickle Cell Anaemia Presenting With Acute Clinical Events: A Single-Center Study.

作者信息

Singh Anwesha, Bokade Chandrakant, Tirpude Bhagyashree, Suryawanshi Milind M, Rohadkar Lakshmikant A

机构信息

Pediatrics and Neonatology, Indira Gandhi Government Medical College and Hospital, Nagpur, IND.

出版信息

Cureus. 2023 May 14;15(5):e39008. doi: 10.7759/cureus.39008. eCollection 2023 May.

DOI:10.7759/cureus.39008
PMID:37378258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10292220/
Abstract

BACKGROUND

Sickle cell disease is a common genetic disorder characterised by chronic haemolytic anaemia and vaso-occlusive crisis. Sickle cell anaemia (SCA) has both short-term effects in the form of acute clinical events and long-term repercussions seen with chronic multiorgan involvement. It is associated with significant morbidity and mortality. In India, the disease is largely undocumented. Thus, there is an urgent need to highlight the features of the disease so that locally appropriate models of care may be implemented.

OBJECTIVE

This study aims to evaluate acute clinical events in SCA and to provide data that may help to reduce the rate of morbidity and mortality associated with this disease by early interventions.

MATERIALS AND METHODS

A cross-sectional observational study was conducted between November 2020 and May 2022 at Indira Gandhi Government Medical College and Hospital, Nagpur, Central India. The inclusion criteria included previously diagnosed patients of SCA (homozygous sickle cell disease) on high-performance liquid chromatography (HPLC) between the age groups of six months and 12 years, presenting with acute clinical events. The exclusion criteria included patients younger than six months and older than 12 years of age, and all patients with other haemoglobinopathies and sickle cell trait. The study was approved by the Institutional Ethical Committee. All the data was entered into a well-designed Microsoft Office Excel spreadsheet (v 2019, Microsoft, Washington, USA). All the clinical, biochemical, and haematological data were tabulated and analysed.

RESULTS

A total of 100 children with sickle cell disease diagnosed by HPLC were enrolled during the study period. About 215 acute clinical events among the 100 cases were recorded, for which they were admitted to the paediatric ward or PICU. The majority (35%, n=35) were seen in the age group of six to nine years (school-going age). About 52% were male and 48% were female (male-to-female ratio= 1.08:1). Pain was the most common symptom. The highest incidence of 36.75% (n=79) was seen with acute painful crises and was the most common indication of hospitalisation, followed by acute febrile illness (AFI) (34.42%, n=74), aplastic crisis (10.23%, n=22), splenic sequestration crisis (9.77%, n=21), hepatobiliary involvement (3.72%, n=8), acute chest syndrome and haemolytic crisis (each 1.86%, n=4), and stroke (1.40%, n=3). In cases of having foetal haemoglobin (HbF) ≥20%, the incidence of acute painful crisis (p=0.0001), hand-foot syndrome (p=0.047), aplastic crisis (p=0.033), splenic sequestration crisis (p=0.039), and AFI (p=0.035) was low as compared to cases having HbF ≤20% which was statistically significant. The incidence of acute painful crisis, hand-foot syndrome, and an aplastic crisis was significantly low in patients receiving hydroxyurea therapy as compared to patients who were not on hydroxyurea. Out of 100 cases, four died during the study period, three died because of splenic sequestration crisis with septic shock, and one died due to hepatic encephalopathy due to haemolytic crisis with septic shock.

CONCLUSION

Acute clinical events in sickle cell disease can have significant morbidity and mortality in the paediatric age group. The nutritional status of sickle cell disease children must be given due importance. Early initiation of hydroxyurea must be encouraged to maintain higher HbF levels, which plays a significant role in reducing morbidity.

摘要

背景

镰状细胞病是一种常见的遗传性疾病,其特征为慢性溶血性贫血和血管闭塞性危机。镰状细胞贫血(SCA)既有急性临床事件形式的短期影响,也有慢性多器官受累导致的长期后果。它与显著的发病率和死亡率相关。在印度,该疾病在很大程度上未被记录。因此,迫切需要突出该疾病的特征,以便实施适合当地情况的护理模式。

目的

本研究旨在评估SCA中的急性临床事件,并提供有助于通过早期干预降低与该疾病相关的发病率和死亡率的数据。

材料与方法

2020年11月至2022年5月在印度中部那格浦尔的英迪拉·甘地政府医学院和医院进行了一项横断面观察性研究。纳入标准包括年龄在6个月至12岁之间、经高效液相色谱法(HPLC)确诊为SCA(纯合子镰状细胞病)且出现急性临床事件的患者。排除标准包括年龄小于6个月和大于12岁的患者,以及所有患有其他血红蛋白病和镰状细胞性状的患者。该研究获得了机构伦理委员会的批准。所有数据都录入了精心设计的Microsoft Office Excel电子表格(v 2019,Microsoft,美国华盛顿)。所有临床、生化和血液学数据都进行了列表和分析。

结果

在研究期间,共纳入了100例经HPLC诊断为镰状细胞病的儿童。100例患者中记录了约215次急性临床事件,为此他们入住了儿科病房或儿科重症监护病房(PICU)。大多数(35%,n = 35)出现在6至9岁年龄组(上学年龄)。约52%为男性,48%为女性(男女比例 = 1.08:1)。疼痛是最常见的症状。急性疼痛性危机的发生率最高,为36.75%(n = 79),是住院最常见的原因,其次是急性发热性疾病(AFI)(34.42%,n = 74)、再生障碍性危象(10.23%,n = 22)、脾梗死危象(9.77%,n = 21)、肝胆受累(3.72%,n = 8)、急性胸综合征和溶血性危机(各1.86%,n = 4)以及中风(1.40%,n = 3)。胎儿血红蛋白(HbF)≥20%的病例中,急性疼痛性危机(p = 0.0001)、手足综合征(p = 0.047)、再生障碍性危象(p = 0.033)、脾梗死危象(p = 0.039)和AFI(p = 0.035)的发生率低于HbF≤20%的病例,差异具有统计学意义。与未接受羟基脲治疗的患者相比,接受羟基脲治疗的患者急性疼痛性危机、手足综合征和再生障碍性危象的发生率显著较低。在100例病例中,4例在研究期间死亡,3例死于脾梗死危象合并感染性休克,1例死于溶血性危机合并感染性休克导致的肝性脑病。

结论

镰状细胞病的急性临床事件在儿童年龄组中可导致显著的发病率和死亡率。必须充分重视镰状细胞病儿童的营养状况。应鼓励早期开始使用羟基脲以维持较高的HbF水平,这在降低发病率方面起着重要作用。

相似文献

1
Clinical Profiles of Children With Sickle Cell Anaemia Presenting With Acute Clinical Events: A Single-Center Study.患有镰状细胞贫血且出现急性临床事件的儿童的临床概况:一项单中心研究。
Cureus. 2023 May 14;15(5):e39008. doi: 10.7759/cureus.39008. eCollection 2023 May.
2
Hydroxyurea (hydroxycarbamide) for sickle cell disease.羟基脲(羟基脲素)用于镰状细胞病。
Cochrane Database Syst Rev. 2017 Apr 20;4(4):CD002202. doi: 10.1002/14651858.CD002202.pub2.
3
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.羟基脲对成年镰状细胞贫血患者死亡率和发病率的影响:长达9年治疗期的风险与益处
JAMA. 2003 Apr 2;289(13):1645-51. doi: 10.1001/jama.289.13.1645.
4
Magnesium for treating sickle cell disease.镁用于治疗镰状细胞病。
Cochrane Database Syst Rev. 2017 Apr 14;4(4):CD011358. doi: 10.1002/14651858.CD011358.pub2.
5
Magnesium for treating sickle cell disease.镁用于治疗镰状细胞病。
Cochrane Database Syst Rev. 2019 Sep 9;9(9):CD011358. doi: 10.1002/14651858.CD011358.pub3.
6
Foetal Haemoglobin and Disease Severity in Nigerian Children with Sickle Cell Anaemia.尼日利亚镰状细胞贫血患儿的胎儿血红蛋白与疾病严重程度
Mediterr J Hematol Infect Dis. 2017 Nov 1;9(1):e2017063. doi: 10.4084/MJHID.2017.063. eCollection 2017.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
The risk of acute events among patients with sickle cell disease in relation to early or late initiation of care at a specialist center: evidence from a retrospective cohort study.镰状细胞病患者在专科中心早启动或晚启动治疗的急性事件风险:一项回顾性队列研究的证据
BMC Pediatr. 2020 Aug 8;20(1):373. doi: 10.1186/s12887-020-02270-y.
9
Clinical and Laboratory Features of Sickle Cell Disease S/D Punjab: Impact of HbF and Hydroxyurea.镰状细胞病S/D旁遮普型的临床和实验室特征:胎儿血红蛋白和羟基脲的影响
Mediterr J Hematol Infect Dis. 2024 May 1;16(1):e2024046. doi: 10.4084/MJHID.2024.046. eCollection 2024.
10
Types of crises in sickle cell disease patients presenting at the haematology day care unit (HDCU), University College Hospital (UCH), Ibadan.在伊巴丹大学学院医院血液科日间护理病房(HDCU)就诊的镰状细胞病患者所出现的危机类型。
West Afr J Med. 2006 Oct-Dec;25(4):284-8.

引用本文的文献

1
Splenic sequestration crisis in children with sickle cell disease in the Eastern region of Saudi Arabia.沙特阿拉伯东部地区镰状细胞病患儿的脾隔离危象
BMC Pediatr. 2025 Sep 1;25(1):672. doi: 10.1186/s12887-025-06020-w.
2
Comparative Proteomic Analysis Reveals Altered Ciliary Proteins in Sickle Cell Disease.比较蛋白质组学分析揭示镰状细胞病中纤毛蛋白的改变
J Proteome Res. 2025 Jun 6;24(6):2981-2995. doi: 10.1021/acs.jproteome.5c00168. Epub 2025 May 15.

本文引用的文献

1
Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.羟脲在尼日利亚中北部乔斯治疗镰状细胞贫血儿童的疗效和安全性。
J Trop Pediatr. 2020 Jun 1;66(3):290-298. doi: 10.1093/tropej/fmz070.
2
Incidence of variant hemoglobins in newborns attended by a public health laboratory.一家公共卫生实验室接诊的新生儿中变异血红蛋白的发病率。
Einstein (Sao Paulo). 2018 Jun 7;16(2):eAO4150. doi: 10.1590/S1679-45082018AO4150.
3
Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.羟基脲对镰状细胞病患者血红蛋白F的增强作用:埃及十年经验
Hemoglobin. 2017 Jul-Nov;41(4-6):267-273. doi: 10.1080/03630269.2017.1408646. Epub 2017 Dec 18.
4
Clinical and laboratory profile of patients with sickle cell anemia.镰状细胞贫血患者的临床和实验室特征
Rev Bras Hematol Hemoter. 2017 Jan-Mar;39(1):40-45. doi: 10.1016/j.bjhh.2016.09.007. Epub 2016 Oct 19.
5
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.羟基脲对镰状细胞贫血儿童和青少年的疗效:一项基于人群的大型回顾性队列研究。
Am J Hematol. 2017 Jan;92(1):77-81. doi: 10.1002/ajh.24587. Epub 2016 Nov 18.
6
Sickle cell disease in India: A perspective.印度的镰状细胞病:一种观点。
Indian J Med Res. 2016 Jan;143(1):21-4. doi: 10.4103/0971-5916.178582.
7
Hospitalization Events among Children and Adolescents with Sickle Cell Disease in Basra, Iraq.伊拉克巴士拉镰状细胞病儿童和青少年的住院事件
Anemia. 2015;2015:195469. doi: 10.1155/2015/195469. Epub 2015 Oct 26.
8
Morbidity pattern in hospitalized under five children with sickle cell disease.五岁以下镰状细胞病住院患儿的发病模式。
Indian J Med Res. 2013 Sep;138(3):317-21.
9
Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience.固定低剂量羟脲治疗印度镰状细胞贫血儿童的疗效:单中心经验。
Indian Pediatr. 2013 Oct;50(10):929-33. doi: 10.1007/s13312-013-0264-0. Epub 2013 Apr 5.
10
Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.低剂量羟基脲可有效降低印度东部镰状细胞贫血患者疼痛性危象的发生率和输血频率。
Hemoglobin. 2012;36(5):409-20. doi: 10.3109/03630269.2012.709897.